Articles from Cofactor Genomics

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics.

Cofactor Genomics announced the latest validation results for OncoPrism®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th Annual Meeting. The talk, presented by Dr. Kevin Flanagan (Cofactor’s VP of Translational Science), “Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform”, highlighted OncoPrism’s dramatic improvement in the prediction of patient responses to cancer immunotherapies relative to other diagnostics. Using an AI approach and RNA expression data from patient tumors, Cofactor’s OncoPrism platform has demonstrated a 300–400% improvement in predictive performance compared to other clinical tests. Cofactor also presented for the first time the validation results for OncoPrism-NSCLC, with non-small cell lung cancer (NSCLC) representing the single largest patient population eligible for immune checkpoint inhibitor (ICI) immunotherapy. Validated with patients enrolled across 12 clinical sites, OncoPrism outperformed PD-L1, with higher sensitivity and specificity in NSCLC.

Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism classifier as a predictive diagnostic 3-4x more capable of identifying patients likely to benefit from immune checkpoint inhibitor immunotherapy (ICI) in Head and Neck Cancer (OncoPrism-HNSCC). These four new cancer profiles also follow the recent announcement of clinical validation and release of a second clinical-use test, OncoPrism-NSCLC, after the successful PREDAPT clinical trial readout from 12 US healthcare systems reporting on OncoPrism’s ability to predict ICI response in NSCLC lung cancer patients.

Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC). The successful readout is announced on the heels of the yearly national PREDAPT Summit, where the participating institutions from across the country gathered and reviewed the study results. The assay was validated in independent HNSCC patient cohorts receiving anti-PD-1 inhibitors pembrolizumab and nivolumab both as a single agent and in combination with chemotherapy. This milestone clears the assay for nationwide clinical use in an interventional setting where doctors can now incorporate OncoPrism to help guide patient treatment in a landscape of multiple therapies, each benefiting a subset of the patient population.

Stanford University and Cofactor Genomics, the company bridging the precision medicine gap, announced today that Stanford will join Cofactor’s PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) ​​clinical trial evaluating use of the company’s OncoPrism™ predictive diagnostic assay across 11 cancers. Cofactor’s patented approach to building multidimensional immune biomarkers powers OncoPrism, which has been shown to predict tumor response to immunotherapy with almost twice the accuracy of PD-L1 tests.

Culmination Bio, a new Intermountain Health Company, and Cofactor Genomics, a predictive diagnostic immunotherapy company, today announced a partnership to leverage samples and data from one of the largest biobanks in the country to fuel the development of Cofactor Genomic’s OncoPrism™ test in 11 cancers.

Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers. OncoPrism is the company’s diagnostic platform that generates multidimensional immune biomarkers using Predictive Immune Modeling. This approach has been shown to predict immunotherapy responders with twice the accuracy of on-market PD-L1 assays, with the added benefit of requiring far less tissue than most commercial tests.